No Data
Morphic Holding Ticks Higher After HSR Waiting Period for Eli Lilly Deal Expires
Morphic Fund Continues Share Buy-Back Effort
Morphic Fund's Latest Stock Buy-Back Figures
Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
RBC Capital Maintains Morphic(MORF.US) With Hold Rating, Maintains Target Price $57
Analysts Have Conflicting Sentiments on These Healthcare Companies: Morphic Holding (MORF), Pyxis Oncology (PYXS) and Zynex (ZYXI)